Manufactures generic APIs and formulations, exporting to the US and other regulated markets alongside domestic branded generics.
Manufactures generic APIs and formulations, exporting to the US and other regulated markets alongside domestic branded generics.
Sells generics in the US through wholesalers and pharmacy chains, where new approvals and price pressure on older products decide the direction, alongside branded drugs sold to Indian doctors and active ingredients sold to other drugmakers. It was demerged from Alembic Limited in 2010, and the Amin family still leads it.
In one line: A mid-sized Indian generics/API exporter.
Moat: narrow (regulatory licence, brand). US FDA-approved plants plus a century-old domestic brand support a dual regulated/branded business.
Headquarters: Vadodara, India · Founded: 1907 · Employees: 20,149
Size Alembic Pharmaceuticals (APLLTD.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $2.20B, the 359th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,044 on 18 Nov 2026.
Performance Over six months the shares gained 39.0%, against -4.9% for the median peer and +3.8% for the India market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 19.7% over the last twelve months (peer median +4.7%); the operating margin is 12.4% (peer median 11.8%).
Valuation It trades at 25.0× forward earnings against a peer median of 17.5× (7th most expensive of 15).
Price implies For today's price to make sense, revenue must grow about 27% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +20 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.1 points below its cost of capital (14.0% WACC).
Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹84.8B | ₹72.2B | ₹65.5B | ₹61.2B | ₹55.7B |
| Revenue growth | — | +10% | +7% | +10% | — |
| Gross profit | ₹38.9B | ₹25.6B | ₹23.2B | ₹21.6B | ₹19.0B |
| EBITDA | ₹14.2B | ₹10.1B | ₹9.04B | ₹8.48B | ₹6.64B |
| Net income | ₹8.44B | ₹6.75B | ₹5.83B | ₹6.16B | ₹3.42B |
| Free cash flow | n/a | ₹2.61B | -₹5.49B | ₹4.30B | ₹2.32B |
| Capital expenditure | n/a | ₹4.95B | ₹5.64B | ₹3.27B | ₹4.43B |
| Total debt | ₹15.5B | ₹14.3B | ₹12.6B | ₹5.13B | ₹7.22B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Alembic Pharmaceuticals APLLTD.NS | $2.20B | +39% | +20% | 12% | 25.0× | 26.7% |
| Aurobindo Pharma AUROPHARMA.NS | $11.0B | +19% | +14% | 15% | 22.3× | 21.1% |
| Lupin LUPIN.NS | $9.67B | -14% | +24% | 24% | 21.0× | 8.8% |
| Cipla CIPLA.NS | $12.2B | +1% | -1% | 13% | 29.1× | 28.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | APLLTD.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +32.1% | -5.5% | highest of 21 |
| 6-month return | +39.0% | -4.9% | 3rd highest of 21 |
| Distance from 52-week high | -2.9% | -29.6% | 3rd highest of 21 |
| Revenue growth (TTM) | +19.7% | +4.7% | 6th highest of 20 |
| Operating margin | 12.4% | 11.8% | 10th highest of 19 |
| Forward P/E | 25.0× | 17.5× | 7th most expensive of 15 |
| Growth the price implies (Req g, 7 yrs) | 26.7% | 2.0% | 4th most demanding of 15 |
| Growth delivered (Del g) | +6.5% | +13.1% | 7th lowest of 15 |
| Hurdle (Req g minus delivered) | +20.2 pp | -0.9 pp | 2nd most demanding of 15 |
| ROIC minus cost of capital | -3.1 pp | -0.4 pp | 7th lowest of 16 |
| EV / EBITDA | 15.4× | 11.8× | 2nd most expensive of 5 |
| Net debt / EBITDA | 0.9× | 0.5× | 4th least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Alembic Pharmaceuticals APLLTD.NS | India | $2.20B | +39% | +20% | 12% | 25.0× | 26.7% | +6.5% |
| Tonghua Dongbao Pharmaceutical 600867.SS | China | $2.19B | -12% | +18% | n/a | 25.4× | 0.9% | +0.3% |
| Zhejiang Hisun Pharmaceutical 600267.SS | China | $2.19B | +14% | -7% | 15% | 15.0× | -9.7% | -1.5% |
| Shandong Buchang Pharmaceuticals 603858.SS | China | $2.25B | -7% | +4% | 10% | n/a | -2.5% | -5.8% |
| PharmaResearch 214450.KS | South Korea | $2.10B | -24% | +29% | 37% | 15.4× | -11.0% | +37.6% |
| Acrobiosystems 301080.SZ | China | $2.31B | +65% | +29% | 17% | 55.2× | 41.3% | +27.7% |
| Haw Par H02.SI | Singapore | $2.08B | -25% | -13% | 30% | 11.9× | 3.2% | +15.7% |
| Regencell Bioscience RGC | United States | $2.33B | -83% | n/a | n/a | n/a | n/a | n/a |
| InnoCare Pharma 688428.SS | China | $2.07B | -7% | +135% | 35% | 85.7× | -10.9% | +344.2% |
| Perrigo PRGO | United States | $2.35B | +52% | -4% | 5% | 6.7× | 14.1% | +0.8% |
| Sam Chun Dang Pharm 000250.KS | South Korea | $2.36B | -66% | +23% | 7% | n/a | n/a | n/a |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.04B | +9% | +5% | 22% | 15.9× | -4.7% | +10.6% |
| NewAmsterdam Pharma NAMS | United States | $2.37B | -45% | -26% | -900% | n/a | n/a | n/a |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.03B | -3% | +9% | 14% | 25.9× | 5.1% | +6.4% |
| HUTCHMED (China) 0013.HK | Hong Kong | $2.38B | +14% | -9% | -6% | 35.9× | 47.0% | +19.3% |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.03B | +19% | -1% | 14% | 16.9× | 1.7% | +15.7% |
| Fujian Cosunter Pharmaceutical 300436.SZ | China | $2.02B | -45% | 0% | -47% | n/a | n/a | n/a |
| Keymed Biosciences 2162.HK | Hong Kong | $2.39B | +7% | 0% | -73% | 18.2× | n/a | n/a |
| InSilico Medicine Cayman TopCo 3696.HK | Hong Kong | $2.40B | -33% | +153% | -7% | 85.2× | 37.9% | +22.9% |
| Prestige Consumer Healthcare PBH | United States | $2.40B | +7% | +5% | 25% | 10.6× | 2.3% | +2.9% |
| Hanall Biopharma 009420.KS | South Korea | $2.01B | +12% | +5% | 3% | n/a | n/a | n/a |